Shineco Subsidiary Registered as a Member of Pharmaceutical Chamber of Commerce
08 June 2023 - 11:00PM
Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a
provider of technologically advanced healthcare products and
services, announced today that in May 2023, its wholly owned
subsidiary. Shineco Life Science Research Co., Ltd., was registered
as a member of the All-China Federation of Industry and Commerce
Medical & Pharmaceutical Chamber of Commerce (the
“Pharmaceutical Chamber of Commerce”), and Ms. Jennifer Zhan, CEO
of Shineco, became a member of the Pharmaceutical Chamber of
Commerce.
The Pharmaceutical Chamber of Commerce is a
national level association that operates directly under the
All-China Federation of Industry and Commerce and is registered
with China’s Ministry of Civil Affairs. The Pharmaceutical Chamber
of Commerce consists of a wide array of pharmaceutical enterprises
throughout China, and it serves as an important link to the
government, supports the interests of its members and serves as a
platform for promoting the industry’s development.
Ms. Jennifer Zhan, CEO of Shineco, commented,
“We are pleased that Shineco Life Science Research has been
registered with the All-China Federation of Industry and Commerce
Medical & Pharmaceutical Industry Chamber of Commerce. I am
also very honored to have been named a director of the
Pharmaceutical Chamber of Commerce for this essential industry
whose products and discoveries help to care for the health and
well-being of people’s lives.”
“We believe that our Company will benefit from
being a member of the Pharmaceutical Chamber of Commerce as it will
enable us to access industry resources, network with other
businesses and professionals in the industry, increase our
visibility in our product areas, and enhance our credibility as
well as our commercial activities. We look forward to taking an
active and productive role to promote our business and the
pharmaceutical industry as a whole.”
There are approximately 1,500 direct members and
more than 50 group members of the Chamber of Commerce that
encompass the entire pharmaceutical industry of more than 5,000
pharmaceutical companies, covering all provinces and municipalities
across China, with eight committees that organize and focus its
activities.
About Shineco, Inc.
Shineco, Inc. (“Shineco” or the “Company) aims
to ’care for a healthy life and improve the quality of life’ by
providing safe, efficient, and high-quality health products and
services to society. Shineco has researched and developed 33 vitro
diagnostic reagents and related medical devices to date, and the
Company also produces and sells healthy and nutritious food. For
more information about Shineco, please visit www.biosisi.com.
Forward-Looking Statements
This news release contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. These forward-looking statements can be
identified by terminology such as “may”, “will”, “should”, “could”,
“intend”, “expect”, “plan”, “budget”, “forecast”, “anticipate”,
“believe”, “estimate”, “predict”, “potential”, “continue”,
“evaluating” or similar words. Forward-looking statements should
not be relied upon because they are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Examples of forward-looking statements include, among
others, statements we make regarding the innovativeness and market
position of our products and services, our competitive strengths.
You are cautioned not to rely on any forward-looking statements.
Actual results may differ materially from historical results or
those indicated by the forward-looking statements as a result of a
variety of factors including, but not limited to, risks and
uncertainties associated with the Company’s ability to raise
additional funding, its ability to maintain and grow its business,
variability of operating results, its ability to maintain and
enhance its brand, its development and introduction of new products
and services, the ability to obtain all necessary regulatory
approvals in the jurisdictions where it intends to market and sell
its products the successful integration of acquired companies,
technologies and assets into its portfolio of products and
services, marketing and other business development initiatives,
competition in the industry, general government regulations,
economic conditions, the impact of the COVID-19 pandemic,
dependence on key personnel, the ability to attract, hire and
retain personnel who possess the technical skills and experience
necessary to meet the requirements of its clients, and its ability
to protect its intellectual property. Shineco encourages you to
review other factors that may affect its future results in its
filings with the Securities and Exchange Commission. The
forward-looking statements in this press release are based only on
information currently available to us and speak only as of the date
of this press release, and Shineco assumes no obligation to update
any forward-looking statements except as required by the applicable
rules and regulations.
For more information, please
contact:
Shineco,Inc.secretary@shineco.techMobile:
+86-010-68130220
Precept Investor Relations LLCDavid J.
Rudnickdavid.rudnick@preceptir.comMobile: +1-646-694-8538
Shineco (NASDAQ:SISI)
Historical Stock Chart
From May 2024 to Jun 2024
Shineco (NASDAQ:SISI)
Historical Stock Chart
From Jun 2023 to Jun 2024